Third, chemotherapy given as part of concurrent chemoradiation may act systemically and potentially eradicate distant micrometastases.

Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...

Adjuvant cancer treatments such as chemotherapy and radiation are given after a primary cancer treatment to help prevent ...

The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC ...

RT-NBTXR3 followed by anti-PD-1 demonstrated favorable safety profile, disease control and tumor response in patients both ...

published in the September 2024 issue of Oncology by O’Brien et al. Resistance to neoadjuvant chemoradiation therapy (neo-CRT) presents a substantial clinical challenge in the management of locally ...

The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

Pembrolizumab plus chemoradiotherapy improved survival in patients with previously untreated, high-risk locally advanced ...

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...